A Comprehensive Review on Ozenoxacin Cream for Treatment of Impetigo
Abstract
A frequent bacterial skin infection in youngsters is impetigo. In contrast to other quinolones like levofloxacin, nadifloxacin, and ofloxacin, ozenoxacin exhibits lower minimum inhibitory concentrations and better antibacterial activity. Because of its limited systemic absorption and lack of known drug interactions, ozenoxacin is notable for not activating cytochrome P450 enzymes in vitro. Despite being a relatively new antibacterial agent, ozenoxacin has been used in clinical settings. To shed light on its efficacy in patients, a meta-analysis has not yet been completed. The purpose of this meta-analysis and systematic review is to assess the effectiveness of ozenoxacin in treating impetigo, specifically when applied as a 1% topical cream.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.